Helix Biopharm (HBP.TO) 1.94 $HBP.TO
Helix BioPharma Corp. Appoints New Independent Chair of the Board
Marketwire Canada - Mon Jul 21, 8:15AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the Company since December 2013 and remains the Chair of the board's Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the Company and President and CEO.
Helix BioPharma Corp. Initiates Enrollment for Ninth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire - Tue Jul 15, 7:32AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the ninth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"
. This follows completion of the first treatment cycle in the three patients enrolled in the eighth dose level cohort, in which L-DOS47 therapy was well tolerated, as reviewed by the Trial Steering Committee.
Helix BioPharma Corp. Announces Completion of Private Placement
Marketwire - Fri Jul 11, 7:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.
Helix BioPharma Corp. Announces the Receipt of Subscription Agreements for a Net CAD5.4 Million Private Placement
Marketwire Canada - Mon Jul 07, 6:25AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for common shares and warrants for aggregate net proceeds in excess of CAD5.4 million after expected expenses. Proceeds of the placement will be used for working capital to support the Company's expanding clinical trial initiatives.
Nasdaq stocks posting largest percentage increases
AP - Fri Jun 27, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Helix BioPharma Corp. Announces Fiscal Q3 2014 Results
Marketwire - Thu Jun 12, 8:02AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three and nine-month periods ended April 30, 2014 and 2013.
Nasdaq stocks posting largest volume increases
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Helix BioPharma Corp. Announces Appointment of New Director and Observer to the Board of Directors
Marketwire Canada - Tue Mar 11, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Sylwester Cacek to the board of directors. Mr. Cacek's appointment was effective March 7, 2014.
Europe's first live trial of LTE Broadcast: revolutionizing video delivery across mobile networks
M2 - Tue Feb 25, 7:26AM CST
- Vodafone Germany and Ericsson trial a unique video broadcast in Borussia Monchengladbach's football stadium
Helix BioPharma Corp. Initiates Enrollment for Seventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Tue Feb 18, 4:42PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the seventh dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle of the three patients enrolled in the sixth dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the Trial Steering Committee.
Helix BioPharma Corp. Appoints New Independent Chair of the Board
Marketwire Canada - Mon Jul 21, 8:15AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the Company since December 2013 and remains the Chair of the board's Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the Company and President and CEO.
Helix BioPharma Corp. Initiates Enrollment for Ninth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire - Tue Jul 15, 7:32AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the ninth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland ("LDOS002"
. This follows completion of the first treatment cycle in the three patients enrolled in the eighth dose level cohort, in which L-DOS47 therapy was well tolerated, as reviewed by the Trial Steering Committee. Helix BioPharma Corp. Announces Completion of Private Placement
Marketwire - Fri Jul 11, 7:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.
Helix BioPharma Corp. Announces the Receipt of Subscription Agreements for a Net CAD5.4 Million Private Placement
Marketwire Canada - Mon Jul 07, 6:25AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for common shares and warrants for aggregate net proceeds in excess of CAD5.4 million after expected expenses. Proceeds of the placement will be used for working capital to support the Company's expanding clinical trial initiatives.
Nasdaq stocks posting largest percentage increases
AP - Fri Jun 27, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Helix BioPharma Corp. Announces Fiscal Q3 2014 Results
Marketwire - Thu Jun 12, 8:02AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three and nine-month periods ended April 30, 2014 and 2013.
Nasdaq stocks posting largest volume increases
AP - Fri Mar 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Helix BioPharma Corp. Announces Appointment of New Director and Observer to the Board of Directors
Marketwire Canada - Tue Mar 11, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Sylwester Cacek to the board of directors. Mr. Cacek's appointment was effective March 7, 2014.
Europe's first live trial of LTE Broadcast: revolutionizing video delivery across mobile networks
M2 - Tue Feb 25, 7:26AM CST
- Vodafone Germany and Ericsson trial a unique video broadcast in Borussia Monchengladbach's football stadium
Helix BioPharma Corp. Initiates Enrollment for Seventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Tue Feb 18, 4:42PM CST
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the seventh dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle of the three patients enrolled in the sixth dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the Trial Steering Committee.
